# Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium

> **NCT00053209** · PHASE2 · COMPLETED · sponsor: **Eastern Cooperative Oncology Group** · enrollment: 46 (actual)

## Conditions studied

- Bladder Cancer
- Transitional Cell Cancer of the Renal Pelvis and Ureter
- Urethral Cancer

## Interventions

- **DRUG:** gemcitabine hydrochloride
- **DRUG:** pemetrexed disodium

## Key facts

- **NCT ID:** NCT00053209
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08-10
- **Primary completion:** 2007-09
- **Final completion:** 2009-05
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2023-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00053209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00053209, "Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00053209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*